SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023)
Por:
Perez-Fidalgo, JA, Gálvez-Montosa, F, Guerra, EM, Madariaga, A, Manzano, A, Martin-Lorente, C, Rubio-Pérez, MJ, Alarcón, J, Barretina-Ginesta, MP, Gaba, L
Publicada:
15 jul 2024
Ahead of Print:
1 jul 2024
Resumen:
In recent years, the incorporation of new strategies to the therapeutic armamentarium has completely changed the outcomes of epithelial ovarian cancer (EOC). The identification of new predictive and prognostic biomarkers has also enabled the selection of those patients more likely to respond to targeted agents. Nevertheless, EOC is still a highly lethal disease and resistance to many of these new agents is common. The objective of this guideline is to summarize the most relevant strategies to manage EOC, to help the clinician throughout the challenging diagnostic and therapeutic processes and to provide evidence-based recommendations.
Filiaciones:
Perez-Fidalgo, JA:
Univ Valencia, Hosp Clin Univ, Biomed Res Inst INCL, Valencia, Spain
Gálvez-Montosa, F:
Hosp Univ Jaen, Jaen, Spain
Guerra, EM:
Hosp Univ Ramon y Cajal, Madrid, Spain
Madariaga, A:
12 Octubre Univ Hosp, Dept Med Oncol, Madrid, Spain
Manzano, A:
Hosp Clin San Carlos, Madrid, Spain
Martin-Lorente, C:
Hosp Santa Creu & Sant Pau, Radiol, Barcelona, Spain
Rubio-Pérez, MJ:
Univ Cordoba UCO, Hosp Univ Reina Sofia, Cordoba, Spain
Alarcón, J:
Hosp Univ Son Espases, Mallorca, Spain
Barretina-Ginesta, MP:
Univ Girona, Inst Invest Biomed Girona IDIBGI, Med Sci Dept, Inst Catala Oncol,Med Oncol Dept,Precis Oncol Grp, Girona, Spain
Gaba, L:
Univ Barcelona, Hosp Clin, Translat Genom & Targeted Therapies Solid Tumors, Med Oncol Dept,IDIBAPS,Dept Med, Barcelona, Spain
hybrid
|